Glypican

AstraZeneca expands US manufacturing footprint to accelerate ambitions in next-generation cell therapy discovery and development

Retrieved on: 
Tuesday, February 6, 2024
Biotechnology, Pharmaceutical, Other Manufacturing, Oncology, General Health, Health, Manufacturing, Clinical Trials, Partnership, Multimedia, Prostate cancer, Cell, Environment, Patient, University, TP53, Ecosystem, Quell, Glypican, IIT, AstraZeneca, Physician, Arm, Acquisition, STEAP2, GPC3, Cancer, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240206590080/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240206590080/en/
    New AstraZeneca facility in Rockville, Maryland (Photo: Business Wire)
    The site represents the latest investment in cell therapy for AstraZeneca following collaborations with Quell therapeutics , AbelZeta, Cellectis , and the acquisition of Neogene Therapeutics.
  • In the US, AstraZeneca’s manufacturing sites focus on the production of small molecules and biologics, harnessing leading pharmaceutical technology and development.
  • AstraZeneca is building a cell therapy portfolio that aims to empower and equip the immune system’s T-cells to more effectively fight cancer.
  • Beyond this, the company is advancing a pipeline of novel T-cell receptor therapies (TCR-Ts) through Neogene Therapeutics, a wholly owned subsidiary of AstraZeneca.

Eureka Therapeutics Awarded $10.6 Million CIRM Grant to Support Clinical Trial of ARTEMIS® T-Cell Therapy in Pediatric Liver Cancer

Retrieved on: 
Tuesday, June 6, 2023
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Hospitals, Clinical Trials, Other Health, GPC3, California Institute for Regenerative Medicine, Partnership, Hepatocellular carcinoma, Survival, AFP, Cancer, Drug, Prognosis, Glypican, HB, Liver cancer, Regenerative medicine, Glypican 3, Patient, CIRM, Hepatoblastoma, Liver, Principal, FDA, Therapy, HCC, Pharmaceutical industry, Vaccine

“We are delighted to partner with CIRM and are honored by their recognition of the potential of our ET140203 ARTEMIS T-cell therapy program,” said Dr. Cheng Liu, President and CEO of Eureka Therapeutics.

Key Points: 
  • “We are delighted to partner with CIRM and are honored by their recognition of the potential of our ET140203 ARTEMIS T-cell therapy program,” said Dr. Cheng Liu, President and CEO of Eureka Therapeutics.
  • “Pediatric liver malignancies are rare, have no FDA-approved treatment options, and remain difficult to treat.
  • The ARYA-1 and ARYA-2 studies use ET140203 ARTEMIS T cells to target AFP-positive liver cancer cells.
  • The ARYA-3 study uses ECT204 ARTEMIS T cells to target the Glypican 3 (GPC3) protein expressed on the surface of liver cancer cells.

Eureka Therapeutics Receives Orphan Drug Designations for Treatment of Hepatoblastoma with ET140203 ARTEMIS® T cells

Retrieved on: 
Monday, October 17, 2022
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, TCR, GPC3, ClinicalTrials.gov, FTD, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Hepatoblastoma, Hepatocellular carcinoma, ODD, HCC, Glypican, Liver cancer, HB, Food, Lymphatic system, Glypican 3, CEO, Adult, Liver, Safety, AFP, FDA, Antigen, Cancer, Pharmaceutical industry, Vaccine, San Francisco Bay Area

These designations highlight the significant unmet medical need for better pediatric liver cancer treatment options.

Key Points: 
  • These designations highlight the significant unmet medical need for better pediatric liver cancer treatment options.
  • The ARYA-1 (adult) and ARYA-2 (pediatric) studies use ET140203 ARTEMIS T cells directed with a TCR mimic antibody to target an alpha fetoprotein (AFP)-peptide/HLA-A2 complex found on liver cancer cells.
  • The ARYA-3 study uses ECT204 T cells to target the Glypican 3 (GPC3) protein expressed on the surface of liver cancer cells.
  • Engineered ET140203 T cells express a TCR-mimic antibody to target an alpha fetoprotein (AFP)-peptide/HLA-A2 complex on liver cancer cells.

Eureka Therapeutics Receives Orphan Drug Designations for Treatment of Hepatocellular Carcinoma (HCC) With ARTEMIS® T Cells

Retrieved on: 
Tuesday, February 8, 2022
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, FTD, HCC, Fast track (FDA), Orphan Drug Act of 1983, ODD, Hepatoblastoma, Hepatocellular carcinoma, Therapy, FDA, Glypican 3, Patient, Safety, Adult, Plasma protein binding, Antigen, TCR, CEO, Liver cancer, HB, Glypican, Lymphatic system, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, GPC3, Food, AFP, Pharmaceutical industry, Vaccine, San Francisco Bay Area

The ARYA-1 and ARYA-2 studies use ET140203 ARTEMIS T cells to target an alpha fetoprotein (AFP)-peptide/HLA-A2 complex found on liver cancer cells.

Key Points: 
  • The ARYA-1 and ARYA-2 studies use ET140203 ARTEMIS T cells to target an alpha fetoprotein (AFP)-peptide/HLA-A2 complex found on liver cancer cells.
  • The ARYA-3 study uses ECT204 T cells to target the Glypican 3 (GPC3) protein expressed on the surface of liver cancer cells.
  • These designations for Eurekas clinical candidates underscore the significant unmet medical need for more effective liver cancer treatment options.
  • Under the Orphan Drug Act, orphan drug status provides incentives, including tax credits, grants and waiver of certain administrative fees for clinical trials, and seven years of market exclusivity following drug approval.

Eureka Therapeutics Announces Initiation of Phase I/II ARYA-2 Clinical Trial of ET140203 ARTEMIS® T Cells to Treat Pediatric Liver Cancer

Retrieved on: 
Wednesday, November 17, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Patient, TCR, CEO, Review, Cancer, Glypican, Lymphatic system, Clinical trial, GPC3, Dana–Farber Cancer Institute, ClinicalTrials.gov, Liver cancer, Medicine, HB, Communication, Adult, Marketing, Hepatocellular carcinoma, Food and Drug Administration, FDA, HCC, Therapy, Liver, Food, Adolescence, AFP, Pharmaceutical industry, Vaccine

We are thrilled to work with Eureka Therapeutics and initiate a trial of ET140203 T-cell therapy for pediatric and adolescent patients with relapsed or refractory liver tumors.

Key Points: 
  • We are thrilled to work with Eureka Therapeutics and initiate a trial of ET140203 T-cell therapy for pediatric and adolescent patients with relapsed or refractory liver tumors.
  • With ARYA-1, ET140203 ARTEMIS T cells target an alpha fetoprotein (AFP)-peptide/HLA-A2 complex found on liver cancer cells.
  • With ARYA-3, ECT204 ARTEMIS T cells target the Glypican 3 (GPC3) protein found on liver cancer cells.
  • Engineered ET140203 T cells express a TCR-mimic antibody to target an alpha fetoprotein (AFP)-peptide/HLA-A2 complex on liver cancer cells.

Eureka Therapeutics Announces Initiation of Phase I/II ARYA-3 Clinical Trial of GPC3 Targeting ARTEMIS® T Cell Therapy in Liver Cancer

Retrieved on: 
Wednesday, July 21, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Medical specialties, Clinical medicine, Cancer, Hepatology, Glypican 3, Hepatocellular carcinoma, Liver cancer, Ovarian cancer, Alpha-fetoprotein, Glypican, AFP-L3

Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the initiation of a Phase I/II clinical trial of ECT204, a GPC3 targeting ARTEMIS T-cell therapy for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer.

Key Points: 
  • Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the initiation of a Phase I/II clinical trial of ECT204, a GPC3 targeting ARTEMIS T-cell therapy for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer.
  • The GPC3 protein is also expressed in other solid tumors including ovarian and lung cancer.
  • With ET140203, the ARTEMIS receptor targets an alpha fetoprotein (AFP)-peptide/HLA-A2 complex found on liver cancer cells using a TCR-mimic antibody.
  • Eureka Therapeutics, Inc. is a privately held clinical-stage biotechnology company focused on developing novel T cell therapies to treat cancers.

Cytovia Therapeutics Partners with National Cancer Institute to Develop Novel Gene-Edited, iPSC-Derived GPC3 CAR NK Cells for the Treatment of Solid Tumors

Retrieved on: 
Wednesday, January 13, 2021
Glypican 3, Branches of biology, Natural killer cell, Cooperative research and development agreement, Glypican

Cytovia has also signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute.

Key Points: 
  • Cytovia has also signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute.
  • Under the CRADA, Cytovia will collaborate with Dr. Hos laboratory to develop and evaluate gene-edited iPSC-derived GPC3 CAR NK cells.
  • Cytovia expects to file an initial new drug application (IND) for its GPC3 CAR NK cells in the first half of 2022.
  • We look forward to collaborating with Dr. Ho, a pioneer in GPC3 research, to develop a novel gene-edited, iPSC-derived GPC3 CAR NK that will advance toward a cure for liver cancer.